07:00 , Sep 12, 2016 |  BioCentury  |  Strategy

Dealing Denali

Denali Therapeutics Inc .'s recent unveiling of 11 deals provides the first glimpse of how the company plans to deploy its nearly $350 million war chest to target neurodegenerative diseases. The company has previously said...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Blaze Bioscience, Denali Therapeutics deal

Denali partnered with Blaze to discover therapeutics at the Fred Hutchinson Cancer Research Center (Seattle, Wash.) that cross the blood-brain barrier (BBB). The partners declined to disclose financial terms. Blaze Bioscience Inc. , Seattle, Wash....
07:00 , Aug 25, 2016 |  BC Extra  |  Top Story

Denali unveils $130M funding, series of deals

Denali Therapeutics Inc. (South San Francisco, Calif.) disclosed Thursday that it raised $130 million in a series B round and made five deals to flesh out its pipeline. The company is pursuing neurodegenerative diseases including...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Eisai, Blaze Bioscience deal

Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent to visualize cancer cells during surgery. The chlorotoxin derivative was isolated...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

BLZ-100: Phase I started

Blaze began an open-label, U.S. Phase I trial of IV BLZ-100 in up to 21 patients with soft tissue sarcoma (STS) who are undergoing surgery. The first part will compare 3 and 12 mg doses...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

BLZ-100: Phase I started

Blaze began an open-label, U.S. Phase I trial to evaluate IV BLZ-100 in up to 30 adult patients undergoing surgical resection of their solid tumors. Blaze Bioscience Inc. , Seattle, Wash.   Product: BLZ-100 (formerly...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

BLZ-100: Phase I started

Blaze began an open-label, dose-escalation, U.S. Phase I trial to evaluate BLZ-100 in up to 27 patients ages <30 with primary CNS tumors. Blaze Bioscience Inc. , Seattle, Wash.   Product: BLZ-100 (formerly CyTP 007...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

BLZ-100: Phase Ib started

Blaze began an open-label, dose-escalation, international Phase Ib trial to evaluate IV BLZ-100 in up to 21 patients with glioma undergoing surgery. BLZ-100 is also in Phase I testing in patients with skin cancer. Blaze...
07:00 , Jul 17, 2014 |  BC Innovations  |  Targets & Mechanisms

New route for old cancer agents

Researchers at the University of Wisconsin-Madison and Cellectar Biosciences Inc. have exploited differences in lipid architecture between cancer and normal cells to create compounds that deliver radiolabels selectively to different types of malignant cells while...
08:00 , Jan 9, 2014 |  BC Innovations  |  Cover Story

Light it up

Poor tumor definition is a central challenge in cancer surgery, which aims to remove all malignant cells while preserving normal tissue. Now, a team from The University of Texas Southwestern Medical Center has designed fluorescent...